Stanley-Laman Group’s Cellectis CLLS Stock Holding History

Stanley-Laman Group’s Portfolio CLLS Stock Details CLLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-8,908	Closed	-$252K	–	226
2018 Q2	$252K	Buy	+8,908	New	+$265K	0.06%	244

Other funds holding CLLS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

TCM

Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return

Stanley-Laman Group's CLLS Position: Q3 2018 in Review

Stanley-Laman Group sold out of Cellectis (CLLS) in Q3 2018, closing a stake of 8,908 shares — an estimated $252K sold.

Stanley-Laman Group first reported a position in CLLS in Q2 2018 and held it in 1 quarter. The position peaked at $252K in Q2 2018. 81 funds tracked by Wall St. Rank hold CLLS as of Q3 2018.

Stanley-Laman Group reported no remaining Cellectis position as of Q3 2018 after selling out during the quarter.
Stanley-Laman Group sold 8,908 Cellectis shares in Q3 2018, an estimated $252K.
Stanley-Laman Group first reported a position in Cellectis in Q2 2018 and held it in 1 quarter.
Stanley-Laman Group's Cellectis position peaked at $252K in Q2 2018.
81 funds tracked by Wall St. Rank held Cellectis as of Q3 2018.

Based on Stanley-Laman Group's 13F filing for Q3 2018, filed 30 Oct 2018.